Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, Length of Stay, and Time to Clinical Stability in Patients With Pneumonia, Sepsis, and Hypercoagulability

NCT07892794 is registered in ClinicalTrials.gov with Universitas Sebelas Maret as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07892794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, Length of Stay, and Time to Clinical Stability in Patients With Pneumonia, Sepsis, and Hypercoagulability
Lead sponsor
Universitas Sebelas Maret
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2025
Completion date
September 30, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Standard Therapy + Placebo Placebo comparatorPlacebo Tablet(s)

    Participants in the placebo comparator group received standard medical treatment for pneumonia complicated by sepsis and hypercoagulability, including appropriate antimicrobial and supportive therapies, together with matching oral placebo tablets. The placebo was administered as one tablet twice daily during hospitalization until clinical stability was achieved according to Halm's Criteria.

  • Standard Therapy + Lumbrokinase DLBS1033 ExperimentalDLBS1033

    Participants in the experimental group received standard medical treatment for pneumonia complicated by sepsis and hypercoagulability, including appropriate antimicrobial and supportive therapies, together with oral Lumbrokinase DLBS1033 (Disolf® 490 mg). The study drug was administered as one tablet twice daily (total daily dose: 980 mg) during hospitalization until clinical stability was achieved according to Halm's Criteria.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Change From Baseline in D-Dimer Level Baseline (Day 0), Day 10, and the clinical stability-related assessment (H+1) during hospitalization.

    Changes in blood D-dimer concentration were evaluated to assess coagulation-related responses to Lumbrokinase DLBS1033. D-dimer levels were measured in ng/mL at baseline (H0), day 10 (H10), and the clinical stability-related assessment (H+1). Changes from baseline were calculated for each participant as the D-dimer concentration at H10 or H+1 minus the baseline concentration at H0. Negative values indicate a reduction in D-dimer levels. The magnitude of change was compared between the Lumbrokinase DLBS1033 and placebo groups.

  • Change From Baseline in Interleukin-6 (IL-6) Level Baseline (Day 0), Day 10, and the clinical stability-related assessment (H+1) during hospitalization.

    Changes in blood interleukin-6 (IL-6) concentration were evaluated to assess the inflammatory response to Lumbrokinase DLBS1033. IL-6 levels were measured in pg/mL at baseline (H0), day 10 (H10), and the clinical stability-related assessment (H+1). Changes from baseline were calculated for each participant as the IL-6 concentration at H10 or H+1 minus the baseline concentration at H0. Negative values indicate a reduction in IL-6 levels. The magnitude of change was compared between the Lumbrokinase DLBS1033 and placebo groups.

Lead sponsor's other trials

Universitas Sebelas Maret, most recent start first.

Similar trials

Same condition (Thrombophilia) and phase, most recent start first.